A Phase II Study of a Three-Drug Combination (Cisplatin, Ifosfamide and Vinorelbine) plus Granulocyte-Colony Stimulating Factor in Advanced Non Small Cell Lung Cancer

Abstract

Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m2 days 1-3, ifosfamide 1500 mg/m2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m2 days 1 and 5; filgrastim was given at the dose of 300 microg subcutaneously from day 8 to day 15. A response rate of 28% was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.

Ifosfamide in Non-Small Cell Lung Cancer

“…The response rate was correlated with dose intensity of vinorelbine (32, 44 and 67%). In seven other studies, different schedules of vinorelbine, ifosfamide and cisplatin were used; 457 patients were treated, with an overall response rate of 46% (range 28–56%) and a median survival of about 11 months, showing a definite activity of VIP regimen, comparable with the most active combinations [30, 31, 32, 33, 34, 35, 36]. In 2002, Souquet et al [37]in a randomized phase III trial used a VIP combination with vinorelbine 25 mg/m 2 on days 1 and 8, ifosfamide 3 g/m 2 on day 1 and cisplatin 75 mg/m 2 on day 1, every 3 weeks; in 126 patients a response rate of 36% was obtained, with a median survival of 8.2 months and 1-year survival of 34%.…”